The natural history study of preclinical genetic Creutzfeldt-Jakob Disease (CJD): a prospective longitudinal study protocol

BMC Neurology

Study Protocol

Gitit Kavé¹  Nurit Omer²  Tamara Shiner³  Noa Bregman³  Roy Alcalay⁴  Tal Glinka⁴  Orly Goldstein⁴  Mali Gana-Weisz⁴  Yifat Alcalay⁵  Nir Giladi⁶  Anat Mirelman⁷  Avner Thaler⁷  Orna Aizenstein⁸  Dafna Ben Bashat⁹ 

[1] Cognitive Neurology Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel;Department of Education and Psychology, The Open University, Ra’anana, Israel;Cognitive Neurology Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel;Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel;Laboratory of early markers of neurodegeneration, Neurological Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel;Cognitive Neurology Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel;Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel;Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel;Laboratory of biomarkers and genomic of neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel;Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel;Division of Clinical Laboratories, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel;Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel;Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel;Brain Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel;Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel;Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel;Laboratory of early markers of neurodegeneration, Neurological Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel;Sagol Brain Institute, Wohl Institute for Advanced Imaging, Sourasky Medical Center, Tel Aviv, Israel;Department of Diagnostic Imaging, Sourasky Medical Center, Tel Aviv, Israel;Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel;Sagol Brain Institute, Wohl Institute for Advanced Imaging, Sourasky Medical Center, Tel Aviv, Israel;

关键词: Creutzfeldt-Jakob Disease;    Genetic Creutzfeldt-Jakob Disease;    Prion disease;    Prodromal CJD;    Biomarkers;    E200K;    Neurodegeneration;    Protocol;    Phenoconversion;   

DOI  :  10.1186/s12883-023-03193-8

 received in 2022-11-29, accepted in 2023-03-30,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundCreutzfeldt-Jakob Disease (CJD) is the most common prion disease in humans causing a rapidly progressive neurological decline and dementia and is invariably fatal. The familial forms (genetic CJD, gCJD) are caused by mutations in the PRNP gene encoding for the prion protein (PrP). In Israel, there is a large cluster of gCJD cases, carriers of an E200K mutation in the PRNP gene, and therefore the largest population of at-risk individuals in the world. The mutation is not necessarily sufficient for the formation and accumulation of the pathological prion protein (PrPsc), suggesting that other, genetic and non-genetic factors affect the age at symptoms onset. Here we present the protocol of a cross-sectional and longitudinal natural history study of gCJD patients and first-degree relatives of gCJD patients, aiming to identify biological markers of preclinical CJD and risk factors for phenoconversion.MethodsThe study has two groups: Patients diagnosed with gCJD, and first-degree healthy relatives (HR) (both carriers and non-carriers of the E200K mutation in the PRNP gene) of patients diagnosed with gCJD. At baseline, and at the end of every year, healthy participants are invited for an “in-depth” visit, which includes a clinical evaluation, blood and urine collection, gait assessment, brain MRI, lumbar puncture (LP), and Polysomnography (PSG). At 6 months from baseline, and then halfway through each year, participants are invited for a “brief” visit, which includes a clinical evaluation, short cognitive assessment, and blood and urine collection. gCJD patients will be invited for one “in-depth” visit, similar to the baseline visit of healthy relatives.DiscussionThis continuous follow-up of the participants and the frequent assessments will allow early identification and diagnosis in case of conversion into disease. The knowledge generated from this study is likely to advance the understanding of the underlying clinicopathological processes that occur at the very beginning of CJD, as well as potential genetic and environmental risk factors for the development of the disease, therefore advancing the development of safe and efficient interventions.Trial registrationThe study is an observational study. It has registered retrospectively in https://clinicaltrials.gov/ and has been assigned an identification number NCT05746715.

【 授权许可】

CC BY   
© The Author(s) 2023. corrected publication 2023

【 图 表 】

Fig. 3

41116_2023_37_Article_IEq213.gif

41116_2023_37_Article_IEq167.gif